Dopamine Agonist Comparison Tool
Dostinex
(Cabergoline)
Once-weekly dosing, minimal GI upset
Bromocriptine
(Parlodel)
Multiple daily doses, higher GI side effects
Quinagolide
(Durapex)
Twice-daily dosing, moderate side effects
Pergolide
(Permax)
Historical use, withdrawn due to heart risks
Medication Details
Select a medication above to view detailed information about its use, dosing, and side effects.
Dosing Calculator
Calculate equivalent doses between medications (based on typical dosing):
Equivalent Dose:
Quick Take
- Dostinex (Cabergoline) is the most convenient dopamine‑agonist for high prolactin levels.
- Bromocriptine works but needs multiple daily doses and more GI upset.
- Quinagolide offers a middle ground - twice‑daily dosing with similar efficacy.
- Older agents like Pergolide are rarely used due to heart‑valve risk.
- Cost, side‑effect profile, and pregnancy plans decide the best pick.
What is Dostinex (Cabergoline)?
When people mention Dostinex is the trade name for a long‑acting dopamine agonist used primarily to lower excess prolactin. Its generic name is Cabergoline, a molecule first approved in the early 1990s for treating hyperprolactinemia and, in lower doses, Parkinson’s disease.
Cabergoline’s high affinity for dopamine D2 receptors lets it suppress prolactin secretion with just once‑or‑twice‑weekly tablets, which is why many patients prefer it over older options.
How Cabergoline Works
Prolactin is a hormone released by the pituitary gland. When dopamine binds to D2 receptors on pituitary lactotroph cells, it tells them to stop making prolactin. Cabergoline mimics dopamine, staying bound for a long time, so prolactin levels drop quickly and stay low.
Because it targets the same pathway as other dopamine agonists, Cabergoline shares therapeutic benefits but usually causes fewer stomach‑related side effects, thanks to its longer half‑life and lower peak concentrations.
Common Alternatives - An Overview
Below are the most frequently prescribed substitutes. Each belongs to the broader class of dopamine agonists
Bromocriptine
Bromocriptine (brand name Parlodel) is a short‑acting ergot‑derived agonist. It was the first drug used for prolactin‑related disorders and remains on the market mainly because it’s cheaper.
Typical dosing starts at 2.5mg daily, divided into two or three doses. Its shorter action means patients often need multiple tablets per day, and nausea or orthostatic hypotension are common complaints.
Quinagolide
Quinagolide (sold as Durapex) is a non‑ergot dopamine agonist introduced in the early 2000s. It provides a middle ground between Cabergoline’s convenience and Bromocriptine’s cost.
Patients usually take 25-50µg twice daily. Side‑effects are generally milder than Bromocriptine but can include headache and dizziness.
Pergolide
Pergolide was once popular for Parkinson’s disease and prolactinomas. However, reports of valvular heart disease led most regulators to withdraw it from routine use.
Because of safety concerns, Pergolide is mentioned here only for historical context; it’s rarely prescribed today.
Generic Cabergoline
Many pharmacies now stock generic Cabergoline. It contains the same active ingredient as Dostinex, priced lower, and follows the same dosing schedule (0.5mg once or twice weekly).
Side‑Effect Snapshot
All dopamine agonists share a core set of possible reactions, but frequency and severity vary.
- Cabergoline/Dostinex: mild nausea, occasional dizziness, rare heart‑valve issues at high doses.
- Bromocriptine: higher rates of nausea, vomiting, low blood pressure, and mood changes.
- Quinagolide: headache, fatigue, occasional leg cramps.
- Pergolide: significant risk of valvular fibrosis, leading to its decline.
Comparison Table
| Drug | Brand | Typical Dose | Main Indications | Key Side Effects | Average AU$/Month |
|---|---|---|---|---|---|
| Cabergoline | Dostinex | 0.5mg 1‑2×/week | Hyperprolactinemia, Parkinson’s (low dose) | Nausea (10‑15%), dizziness, rare valve issues | $45‑$70 |
| Bromocriptine | Parlodel | 2.5‑5mg daily (split) | Hyperprolactinemia, acromegaly | Nausea (30‑40%), hypotension, mood swings | $20‑$35 |
| Quinagolide | Durapex | 25‑50µg twice daily | Hyperprolactinemia | Headache, dizziness, leg cramps | $30‑$45 |
| Pergolide | Permax | 0.5‑1mg daily | Parkinson’s (historical) | Valvular fibrosis, nausea | - (withdrawn) |
How to Choose the Right Option
Picking a therapy isn’t just about price. Consider these factors:
- Efficacy: All four agents lower prolactin, but Cabergoline often reaches target levels faster.
- Dosing convenience: Once‑weekly tablets beat three‑times‑daily regimens for adherence.
- Side‑effect tolerance: If you’re prone to nausea, Bromocriptine may be a deal‑breaker.
- Cost and insurance coverage: Generic Cabergoline matches Dostinex’s efficacy at a lower price, while Bromocriptine remains the cheapest.
- Future pregnancy plans: Cabergoline is class‑B in Australia (generally safe), whereas Bromocriptine has more mixed data.
Talk with your endocrinologist about your lifestyle, any heart‑valve screening results, and how quickly you need prolactin normalized.
Practical Tips & Common Pitfalls
- Take Cabergoline with food to reduce stomach upset.
- If you miss a dose, wait until the next scheduled day - don’t double up.
- Regularly check prolactin levels every 4‑6 weeks after starting or adjusting dose.
- For Bromocriptine, start with a low dose and increase slowly to improve tolerance.
- Anyone on Pergolide should have an annual echocardiogram; most clinicians now avoid it altogether.
Frequently Asked Questions
Is Cabergoline safe for long‑term use?
Yes, most studies show Cabergoline can be used for years without serious problems. Regular monitoring of heart valves is recommended only if doses exceed 2mg per week.
Can I switch from Bromocriptine to Cabergoline?
Switching is common. Your doctor will taper Bromocriptine over a week or two, then start Cabergoline at a low weekly dose to avoid a sudden drop in dopamine activity.
What if I become pregnant while on Cabergoline?
Cabergoline is classified as pregnancy‑category B in Australia, meaning animal studies haven’t shown risk and there’s limited human data. Most specialists discontinue it once pregnancy is confirmed and monitor prolactin levels.
Why does Bromocriptine cause more nausea than Cabergoline?
Bromocriptine peaks quickly in the bloodstream, irritating the stomach lining. Cabergoline’s longer half‑life results in slower, steadier dopamine receptor activation, which is gentler on the gut.
Is Quinagolide available in Australia?
Quinagolide is approved in Europe but not currently listed on the Australian Therapeutic Goods Register. Some patients may obtain it via overseas pharmacies, but doctors usually prefer locally approved options.
Do I need regular blood tests while on these drugs?
Yes. Track prolactin levels, liver function, and, for high‑dose Cabergoline, an echocardiogram every 1‑2years. Bromocriptine may also require blood pressure monitoring.
Comments (17)
Vaibhav Sai
Ah, the elegance of Dostinex! Its once‑weekly dosing feels like a breath of fresh air, especially when you compare it to the multi‑daily regimen of bromocriptine. Plus, the GI upset is practically negligible, which is a delightful bonus for anyone sensitive to nausea. The cost, while a tad higher than the cheap alternatives, still remains reasonable for the convenience it offers. Overall, it’s a solid pick for most patients dealing with hyperprolactinemia.
Lindy Swanson
Honestly, I think the hype around Dostinex is overrated; bromocriptine’s longer track record and lower price make it the real workhorse, even if you have to take it more often.
Amit Kumar
Totally get where you're coming from! 😄 While bromocriptine is cheap, many folks love the simplicity of a weekly pill. The fewer pills, the fewer chances to forget a dose, right? 🚀
Crystal Heim
Bringing in the facts: bromocriptine’s side‑effect profile is considerably harsher-think nausea for up to 40% of patients-whereas cabergoline keeps that down to single‑digit percentages.
Sruthi V Nair
The balance between efficacy and tolerability is crucial; cabergoline’s dopamine‑receptor affinity gives it an edge, yet the underlying pharmacodynamics of quinagolide deserve more attention for those seeking intermediate dosing frequencies.
kevin tarp
Just a quick note: the typical cabergoline dose is 0.5 mg once or twice weekly, not daily. Mixing up the schedule can lead to unnecessary side‑effects.
ravi kumar
In India we’ve seen how local manufacturing keeps costs down, but quality control matters. Cabergoline produced here meets global standards, making it a patriotic yet practical choice.
SandraAnn Clark
It’s just another pill.
Rex Wang
True, it’s simple-but simplicity can be a huge relief for patients juggling multiple meds.
mark Lapardin
From a pharmacokinetic standpoint, cabergoline’s prolonged half‑life translates into a steady-state plasma concentration that minimizes peak‑related adverse events, whereas bromocriptine’s shorter half‑life necessitates split dosing to maintain therapeutic levels, inadvertently increasing gastrointestinal irritation.
KIRAN nadarla
When dissecting the comparative efficacy of dopamine agonists for hyperprolactinemia, one must first acknowledge the pharmacodynamic nuances that differentiate cabergoline from its counterparts. Cabergoline exhibits a markedly higher affinity for D2 receptors, which translates into a more potent inhibition of prolactin secretion. Furthermore, its extended half‑life allows for once‑weekly administration, reducing the burden of adherence-a factor that cannot be overstated in chronic therapy. In contrast, bromocriptine, while historically the first‑line agent, suffers from a comparatively lower receptor affinity and a shorter half‑life, compelling patients to adhere to multiple daily doses. This dosing frequency not only amplifies the risk of missed doses but also heightens the incidence of nausea, an adverse effect reported in up to 40% of users. Quinagolide, positioned as a middle ground, offers twice‑daily dosing with a side‑effect profile that sits between the two extremes, yet its clinical data pool remains less robust. Additionally, the withdrawn pergolide serves as a cautionary tale; its association with valvular heart disease underscores the importance of post‑marketing surveillance and risk assessment. From a cost–benefit perspective, cabergoline’s higher price point is offset by its superior tolerability and reduced need for dose adjustments, resulting in lower overall healthcare utilization. Moreover, meta‑analyses consistently demonstrate higher rates of prolactin normalization with cabergoline versus bromocriptine. Lastly, patient preference studies reveal a clear inclination towards regimens that minimize daily pill burden, reinforcing the practical advantages of cabergoline in real‑world settings. In sum, while each agent has its niche, the convergence of pharmacologic potency, dosing convenience, and safety profile positions cabergoline as the preeminent choice for most patients suffering from hyperprolactinemia.
Kara Guilbert
i cant beleve ppl still ignore the riks, its not just a simple pill, think abot the heart!
Sonia Michelle
From a holistic viewpoint, the journey to normalizing prolactin levels is as much about patient empowerment as it is about pharmacology; providing clear information on dosing schedules helps individuals take ownership of their health.
Neil Collette
Oh, sure, because “patient empowerment” magically solves the fact that some of these drugs were pulled from the market for good reason. Good luck with that optimism.
James Lee
These meds are kinda same, idk why ppl make a big deal.
Dennis Scholing
Dear community, I would like to emphasize that when selecting a dopamine agonist, clinicians should consider both the pharmacologic profile and the patient’s personal circumstances, ensuring an individualized approach that aligns with evidence‑based guidelines.
kenneth strachan
Alright, let’s flip the script-maybe the “best” drug is whatever the insurance decides to cover, because in the end, economics beats science every single time.